Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukine-2 treatment.

Szczegóły

Tytuł:: Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukine-2 treatment.
Autorzy:: Weiss M; Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France.
de Masson A; Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France.
Robin M; Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France.
Peffault de Latour R; Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France.
Bagot M; Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France.
Socié G; Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France.
Bouaziz JD; Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France.
Źródło:: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2020 Dec; Vol. 34 (12), pp. e791-e793. Date of Electronic Publication: 2020 Aug 26.
Typ publikacji:: Letter
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992-
MeSH Terms:: Graft vs Host Disease*/drug therapy
Scleroderma, Localized*/drug therapy
Scleroderma, Systemic*
Skin Diseases*
Bone Marrow Transplantation ; Chronic Disease ; Humans ; Interleukin-2 ; Remission Induction
References:: JagasiaMH, Greinix HT, Arora Met al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 2015; 21: 389-401.e1.
Strong RodriguesK, Oliveira-Ribeiro C, de Abreu Fiuza Gomes, SKnobler R. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol 2018; 19: 33-50.
KorethJ, Antin JH. Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol 2008; 1: 111.
YeC, Brand D, Zheng SG. Targeting IL-2: an unexpected effect in treating immunological diseases. Signal Transduct Target Ther 2018; 3: 2.
KorethJ, Matsuoka K, Kim HTet al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055-2066.
ZornE, Kim HT, Lee SJet al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903-2911.
Substance Nomenclature:: 0 (Interleukin-2)
Entry Date(s):: Date Created: 20200425 Date Completed: 20210514 Latest Revision: 20210514
Update Code:: 20240105
DOI:: 10.1111/jdv.16524
PMID:: 32329912
: Opinia redakcyjna

Full Text Finder

Informacja